Cargando…
Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer
BACKGROUND: Myeloid derived suppressor cells (MDSC) are important regulators of immune responses. We evaluated the mechanistic role of MDSC depletion on antigen presenting cell (APC), NK, T cell activities and therapeutic vaccination responses in murine models of lung cancer. PRINCIPAL FINDINGS: Ind...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398024/ https://www.ncbi.nlm.nih.gov/pubmed/22815789 http://dx.doi.org/10.1371/journal.pone.0040677 |
_version_ | 1782238233909788672 |
---|---|
author | Srivastava, Minu K. Zhu, Li Harris-White, Marni Kar, Upendra Huang, Min Johnson, Ming F. Lee, Jay M. Elashoff, David Strieter, Robert Dubinett, Steven Sharma, Sherven |
author_facet | Srivastava, Minu K. Zhu, Li Harris-White, Marni Kar, Upendra Huang, Min Johnson, Ming F. Lee, Jay M. Elashoff, David Strieter, Robert Dubinett, Steven Sharma, Sherven |
author_sort | Srivastava, Minu K. |
collection | PubMed |
description | BACKGROUND: Myeloid derived suppressor cells (MDSC) are important regulators of immune responses. We evaluated the mechanistic role of MDSC depletion on antigen presenting cell (APC), NK, T cell activities and therapeutic vaccination responses in murine models of lung cancer. PRINCIPAL FINDINGS: Individual antibody mediated depletion of MDSC (anti-Gr1 or anti-Ly6G) enhanced the antitumor activity against lung cancer. In comparison to controls, MDSC depletion enhanced the APC activity and increased the frequency and activity of the NK and T cell effectors in the tumor. Compared to controls, the anti-Gr1 or anti-Ly6G treatment led to increased: (i) CD8 T cells, (ii) NK cells, (iii) CD8 T or NK intracytoplasmic expression of IFNγ, perforin and granzyme (iv) CD3 T cells expressing the activation marker CD107a and CXCR3, (v) reduced CD8 T cell IL-10 production in the tumors (vi) reduced tumor angiogenic (VEGF, CXCL2, CXCL5, and Angiopoietin1&2) but enhanced anti-angiogenic (CXCL9 and CXCL10) expression and (vii) reduced tumor staining of endothelial marker Meca 32. Immunocytochemistry of tumor sections showed reduced Gr1 expressing cells with increased CD3 T cell infiltrates in the anti-Gr1 or anti-Ly6G groups. MDSC depletion led to a marked inhibition in tumor growth, enhanced tumor cell apoptosis and reduced migration of the tumors from the primary site to the lung compared to controls. Therapeutic vaccination responses were enhanced in vivo following MDSC depletion with 50% of treated mice completely eradicating established tumors. Treated mice that rejected their primary tumors acquired immunological memory against a secondary tumor challenge. The remaining 50% of mice in this group had 20 fold reductions in tumor burden compared to controls. SIGNIFICANCE: Our data demonstrate that targeting MDSC can improve antitumor immune responses suggesting a broad applicability of combined immune based approaches against cancer. This multifaceted approach may prove useful against tumors where MDSC play a role in tumor immune evasion. |
format | Online Article Text |
id | pubmed-3398024 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-33980242012-07-19 Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer Srivastava, Minu K. Zhu, Li Harris-White, Marni Kar, Upendra Huang, Min Johnson, Ming F. Lee, Jay M. Elashoff, David Strieter, Robert Dubinett, Steven Sharma, Sherven PLoS One Research Article BACKGROUND: Myeloid derived suppressor cells (MDSC) are important regulators of immune responses. We evaluated the mechanistic role of MDSC depletion on antigen presenting cell (APC), NK, T cell activities and therapeutic vaccination responses in murine models of lung cancer. PRINCIPAL FINDINGS: Individual antibody mediated depletion of MDSC (anti-Gr1 or anti-Ly6G) enhanced the antitumor activity against lung cancer. In comparison to controls, MDSC depletion enhanced the APC activity and increased the frequency and activity of the NK and T cell effectors in the tumor. Compared to controls, the anti-Gr1 or anti-Ly6G treatment led to increased: (i) CD8 T cells, (ii) NK cells, (iii) CD8 T or NK intracytoplasmic expression of IFNγ, perforin and granzyme (iv) CD3 T cells expressing the activation marker CD107a and CXCR3, (v) reduced CD8 T cell IL-10 production in the tumors (vi) reduced tumor angiogenic (VEGF, CXCL2, CXCL5, and Angiopoietin1&2) but enhanced anti-angiogenic (CXCL9 and CXCL10) expression and (vii) reduced tumor staining of endothelial marker Meca 32. Immunocytochemistry of tumor sections showed reduced Gr1 expressing cells with increased CD3 T cell infiltrates in the anti-Gr1 or anti-Ly6G groups. MDSC depletion led to a marked inhibition in tumor growth, enhanced tumor cell apoptosis and reduced migration of the tumors from the primary site to the lung compared to controls. Therapeutic vaccination responses were enhanced in vivo following MDSC depletion with 50% of treated mice completely eradicating established tumors. Treated mice that rejected their primary tumors acquired immunological memory against a secondary tumor challenge. The remaining 50% of mice in this group had 20 fold reductions in tumor burden compared to controls. SIGNIFICANCE: Our data demonstrate that targeting MDSC can improve antitumor immune responses suggesting a broad applicability of combined immune based approaches against cancer. This multifaceted approach may prove useful against tumors where MDSC play a role in tumor immune evasion. Public Library of Science 2012-07-16 /pmc/articles/PMC3398024/ /pubmed/22815789 http://dx.doi.org/10.1371/journal.pone.0040677 Text en This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Srivastava, Minu K. Zhu, Li Harris-White, Marni Kar, Upendra Huang, Min Johnson, Ming F. Lee, Jay M. Elashoff, David Strieter, Robert Dubinett, Steven Sharma, Sherven Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer |
title | Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer |
title_full | Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer |
title_fullStr | Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer |
title_full_unstemmed | Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer |
title_short | Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer |
title_sort | myeloid suppressor cell depletion augments antitumor activity in lung cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398024/ https://www.ncbi.nlm.nih.gov/pubmed/22815789 http://dx.doi.org/10.1371/journal.pone.0040677 |
work_keys_str_mv | AT srivastavaminuk myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer AT zhuli myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer AT harriswhitemarni myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer AT karupendra myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer AT huangmin myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer AT johnsonmingf myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer AT leejaym myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer AT elashoffdavid myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer AT strieterrobert myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer AT dubinettsteven myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer AT sharmasherven myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer |